• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
IDXG

IDXG

Interpace Biosciences, Inc.

OTCHealthcareMedical - Diagnostics & ResearchUS

USD1.75

-0.01 (-0.57%)

Rating:A-

Company Profile

CEO

Thomas W. Burnell

IPO Date

1998-05-20

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

OTC

Country

US

Market Metrics

Open

$1.70

Prev. Close

$1.76

Day Low

$1.70

Day High

$1.75

52W Low

$0.70

52W High

$2.40

Market Cap

$0.05B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

31.9%

Avg Negative

1.4%

Avg Neutral

66.9%

News Feed

Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why

Zacks Investment Research·7/1/2021·↑ positive

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

GlobeNewsWire·5/11/2021·↑ positive

Interpace Biosciences Raises Full Year 2021 Revenue Guidance

GlobeNewsWire·4/19/2021·↑ positive

Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis

GlobeNewsWire·4/12/2021·↑ positive

Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®

GlobeNewsWire·4/5/2021·↑ positive

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

GlobeNewsWire·3/31/2021·↑ positive

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR

GlobeNewsWire·3/17/2021·↑ positive

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

GlobeNewsWire·2/25/2021·↑ positive

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

GlobeNewsWire·2/24/2021·↑ positive

Interpace Biosciences Announces Path Forward in Letter to Shareholders

GlobeNewsWire·2/16/2021·↑ positive